VRC-HIVADV014-00-VP placebo

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

CompletedNCT00123968

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2006-05-31End: 2012-06-30Updated: 2021-11-09

Phase 2

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

CompletedNCT00125970

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2005-09-30End: 2010-01-31Updated: 2021-10-15

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

WithdrawnNCT00498056

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Updated: 2021-11-01

Related Papers

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

PLoS Pathogens2021-11-292 citations

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

2011-08-03117 citations

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

2010-02-0182 citations

Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa.

2009-04-1021 citations